Inner Banner


Send to friends
Your Email :*
Friend Email :*
Your Name :
Your Massage :
Security Code:*
Rate it : 

Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested.



Recommended Adult Dose:


  • Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily. (2.1)
  •  Recommended Pediatric Dose: Newly Diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI therapy: 230 mg/m2 orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg).


 Eligible newly diagnosed adult patients with Ph+ CML-CP who have received Nilotinib for a minimum of 3 years and have achieved a sustained molecular response (MR4.5) and patients with Ph+ CML-CP resistant or intolerant to imatinib who have received Nilotinib for at least 3 years and have achieved a sustained molecular response (MR4.5) may be considered for treatment discontinuation.

  • Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
  •  Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.
  •  Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.


  • Myelosuppression: Monitor CBC during therapy and manage by treatment interruption or dose-reduction.
  •  Cardiac and Arterial Vascular Occlusive Events: Evaluate cardiovascular status, monitor and manage cardiovascular risk factors during Nilotinib therapy.
  •  Pancreatitis and elevated serum lipase: Monitor serum lipase; if elevations are accompanied by abdominal symptoms, interrupt doses and consider appropriate diagnostics to exclude pancreatitis.
  •  Hepatotoxicity: Monitor hepatic function tests monthly or as clinically indicated.
  •  Electrolyte abnormalities: Nilotinib can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to initiating Nilotinib and monitor periodically during therapy.
  •  Tumor lysis syndrome: Maintain adequate hydration and correct uric acid levels prior to initiating therapy with Nilotinib.
  •  Hemorrhage: Hemorrhage from any site may occur. Advise patients to report signs and symptoms of bleeding and medically manage as needed.
  •  Fluid retention: Monitor patients for unexpected rapid weight gain, swelling, and shortness of breath. Manage medically.
  •  Effects on Growth and Development in Pediatric Patients: Monitor growth and development in pediatric patients.
  •  Embryo-Fetal toxicity: Advise patients of potential risk to a fetus and to use effective contraception.



  • Strong CYP3A inhibitors: Avoid concomitant use with Nilotinib, or reduce Nilotinib dose if co-administration cannot be avoided.
  •  Strong CYP3A inducers: Avoid concomitant use with Nilotinib.
  •  Proton Pump Inhibitors: Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors




How do you evaluate the quality and performance of this product if you used this product?

comments header
Send comment
Mehrad one year ago

I used this product before and was very pleased. I suggest buying.

Manager one year ago

Thank you for your comment

similar products